Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections
Thirty-day mortality was similar in a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections treated with ceftazidime-avibactam or meropenem-vaborbactam. Emergence of resistance was higher in the ceftazidime-avibactam group (12% vs 0%); putative resistance mechanisms included porin mutations (<i>Klebsiella pneumoniae</i>) and R2 loop structural changes in AmpC (<i>Enterobacter cloacae</i> complex).
Authors
- Sara E. Cosgrove (ORCID: https://orcid.org/0000-0001-9458-4331)
- Sara M. Karaba (ORCID: https://orcid.org/0000-0001-8452-5549)
- Armani M. Hawes (ORCID: https://orcid.org/0000-0002-5474-0587)
- José Luis Martínez (ORCID: https://orcid.org/0000-0001-8813-7607)
- Yehudit Bergman (ORCID: https://orcid.org/0000-0002-4262-7173)
- Dariusz A Hareza (ORCID: https://orcid.org/0000-0002-5425-7958)
- Jose Manuel Munita (ORCID: https://orcid.org/0000-0002-7870-1056)
- Pranita D. Tamma
- Patricia J. Simner
- Zackery P. Bulman
Institutions
- Universidad del Desarrollo (CL)
- Johns Hopkins University (US)
- American Association of Colleges of Pharmacy (US)
- Johns Hopkins Medicine (US)
- Clínica Alemana (CL)
- University of Illinois Chicago (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1128/aac.01602-25
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00